Use of mda-5 as an antiviral and antiproliferative agent

Abstract

The present invention relates to mda-5 nucleic acids, MDA-5 proteins, the mda-5 promoter, and related molecules, and the use of each of these elements in protecting against or limiting viral infection, controlling cell proliferation, and promoting apoptosis. It is based upon the discovery that, contrary to earlier hypotheses based on the amino acid sequence of MDA-5, the protein is not a defective ATPase but rather exhibits ATPase activity. This supports the role of MDA-5 as a RNA helicase protein and consequently its use in promoting RNA degradation, for example in the context of antiviral defense, limitation of cell proliferation, or induction of apoptosis.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 10 / 055,475, filed Jan. 22, 2002 which is a continuation-in-part of International Patent Application No. PCT / US01 / 06960, filed Feb. 28, 2001 and published in English on Sep. 7, 2001 as Publication No. WO 01 / 64707, which is a continuation-in-part of U.S. patent application Ser. No. 09 / 515,363, filed Feb. 29, 2000.[0002] The subject matter described herein was developed at least in part using funds provided by National Institutes of Health Grants CA35675 and CA74468, so that the United States Government has certain rights to this patent application.1. INTRODUCTION [0003] The present invention relates to melanoma differentiation associated gene-5 (mda-5) nucleic acids, MDA-5 proteins, and the mda-5 gene promoter and related molecules, and the use of these elements to protect against or limit viral infection, to control cell proliferation and to induce apoptotic cell death. It is based, at least in part, on the...

AI Technical Summary

Benefits of technology

"The present invention is related to the use of mda-5 nucleic acids, proteins, and related molecules to protect against or limit viral infection, control cell proliferation, and promote apoptosis. The invention is based on the discovery that mda-5 is not a defective ATPase but exhibits ATPase activity, which supports its role as a RNA helicase protein and promoting RNA degradation. The technical effect of this invention is the development of new tools to protect against viral infection and promote cell fate control."

Problems solved by technology

However, this process can go awry in cancer cells, resulting in uncontrolled proliferation and an inability to respond to normal growth-inhibitory signals (Fisher et al., 1985, Pharmacol Ther 27(2):143-66; Waxman S., 1995, Differentiation Therapy, Waxman, ed., Sereno Symposium Publications: Rome, Italy. pp.

Moreover, as cancer cells evolve, ultimately developing new phenotypes or acquiring a further elaboration of pre-existing transformation-related properties, the expression of differentiation-associated traits often undergoes a further decline.

PCT / US01 / 06960 suggests that because of this sequence divergence, MDA-5 may not bind ATP effectively, and therefore may be an ATPase defective helicase, or may require a different energy source and / or metals for activity.

Images